| Editor's Note: Fierce PM Tracker will not publish on Thursday or Friday in observance of the Thanksgiving holiday. We’ll be back in your inbox on Monday. Have a great weekend! |
|
Tuesday, December 5, 2023 | 1pm ET / 10am PT Join us to learn more about what impact deep engineering engagement and an enterprise-grade cloud platform can provide and how a leading life science organization is incorporating AI to accelerate its initiatives. Register now.
|
|
Today’s Big NewsNov 22, 2023 |
|
Decemeber 5, 2023 | The Edison Ballroom, NYC A celebration of the 50 key players, changemakers and innovators across biotech, pharma and healthcare. The Fierce 50 is a groundbreaking project to identify, elevate and celebrate the individuals and companies driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. Register Now!
|
|
| By Max Bayer CRISPR Therapeutics laid off some of its staffers a week after FDA advisers endorsed the company's Vertex-sponsored, gene-edited cell therapy, according to the three sources. The company reported having more than $1.7 billion in cash as of the end of September. |
|
|
|
By Kevin Dunleavy Unable to scale up its manufacturing fast enough to meet the spiraling demand for its GLP-1 weight loss products, Novo Nordisk is employing a new strategy—reducing production of diabetes drug Victoza to make more Ozempic. |
By Andrea Park About a year after beginning its full market launch, Masimo’s W1 smartwatch can now be used as a medical device in the U.S. |
By Nick Paul Taylor Evelo Biosciences is dissolving. One month after starting a search for strategic alternatives, the Flagship Ventures-backed microbiome biotech has found its only option is to close its doors and hand any cash to creditors. |
|
Tuesday, December 5, 2023 | 11am ET / 8am PT Clinical pharmacology information comprises more than 50% of a drug label. Join us for this objective webinar to review the clinical pharmacology-related regulatory hurdles that may lead to review issues or impact approvability of marketing applications, and discuss strategies to mitigate these. Register now.
|
|
By Conor Hale After the collapse of Bioventus’ efforts to acquire its previous orthopedic partner CartiHeal last year, Smith+Nephew has swooped in to pick up the sports medicine developer—and at a discount. |
By Fraiser Kansteiner After suffering setbacks in the clinic and in court this week, Bayer’s ability to overhaul its corporate structure is becoming more constricted, one group of analysts contends. |
By Gabrielle Masson Boehringer Ingelheim is acquiring bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to $508 million. |
By Andrea Park As competitor Philips continues to grapple with the effects of its long-standing recall of CPAP machines and other respiratory devices, ResMed is now issuing a safety warning of its own. |
By Nick Paul Taylor InDex Pharmaceuticals may be struggling to think of reasons to be thankful. The Swedish biotech has rocked investors with news it is stopping a phase 3 ulcerative colitis trial early in response to lackluster efficacy, sending its share price down 60%. |
By Angus Liu Novartis has withdrawn its request to access Takeda’s documents as part of an investigation over potential trade-secrets theft. |
By James Waldron After mulling a potential buyout for a month, Freeline Therapeutics has decided that its future lies in the arms of its majority shareholder. |
Fierce podcastsDon’t miss an episode |
| This episode of "The Top Line" is dedicated to Alzheimer’s disease, spotlighting the latest treatments and what lies ahead. Fierce Pharma's Fraiser Kansteiner discusses Leqembi's full approval with Eisai's Alexander Scott. Annalee Armstrong from Fierce Biotech interviews Alzheimer's expert Howard Fillit, M.D., exploring groundbreaking research. Fierce Pharma’s Eric Sagonowsky speaks with Reisa Sperling, M.D., about Leqembi's potential in preventing Alzheimer’s progression before symptoms emerge. |
|
|---|
|
|
|
Tuesday, November 28, 2023 | 11am ET / 8am PT Elevate your biopharmaceutical game! Join our webinar to explore game-changing solutions. Uncover the power of Recombumin® rHA – the consistent, animal-free alternative revolutionizing manufacturing. Don't miss this chance to stay ahead in the advanced therapy landscape.
|
|
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
